StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN) PT Raised to $202 at BMO Capital Amid Positive Repatha Data
February 3, 2017 6:53 AM
BMO Capital raised its price target on Amgen (NASDAQ: AMGN) to $202.00 (from $197.00) while maintaining a Outperform rating following ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
FDA
Next Articles
Amgen (AMGN) PT Raised to $175 at Oppenheimer
February 3, 2017 6:21 AM
Amgen (AMGN) Tops Q4 EPS by 10c, Offers FY Guidance
February 2, 2017 4:23 PM
Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
February 2, 2017 4:21 PM
Amgen's (AMGN) Repatha Trail Met Primary Endpoint in Reducing Risk of Cardiovascular Events
February 2, 2017 4:01 PM
Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
February 2, 2017 4:00 PM
